Cutaneous squamous cell carcinoma

What changed: Cutaneous squamous cell carcinoma

Cancer page →

Every dated change on the records linked to Cutaneous squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval3Regulatory4Guideline1Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-08This recordCutaneous squamous cell carcinoma
Facts on this page last checked
When this page itself was last checked or edited.

October 2025 · 1

2025-10RegulatoryCemiplimab
Cemiplimab: approval (US)
Adjuvant high-risk CSCC after surgery and radiation (C-POST)

2025 · 3

December 2024 · 1

2024-12-13RegulatoryCosibelimab
Cosibelimab: approval (US)
Approved for cSCC

2024 · 2

December 2023 · 1

2023-12RegulatoryCosibelimab
Cosibelimab: complete response letter (US)
Complete response letter citing third-party manufacturing inspection findings

2022 · 1

2022MilestoneCemiplimab
Neoadjuvant cemiplimab: 51% pathological complete response (NEJM)
A milestone in how this cancer is treated.

2020 · 1

2020MilestonePembrolizumab
Pembrolizumab approved (KEYNOTE-629)
A milestone in how this cancer is treated.

September 2018 · 1

2018-09-28RegulatoryCemiplimab
Cemiplimab: approval (US)
Advanced cutaneous squamous cell carcinoma: first systemic therapy approved for CSCC

2018 · 2

2011 · 1

2011MilestoneCetuximab
Cetuximab activity in unresectable cSCC (phase 2)
A milestone in how this cancer is treated.

1938 · 1

1938MilestoneCutaneous squamous cell carcinoma
Mohs micrographic surgery introduced
A milestone in how this cancer is treated.